Pharmacist Medication Insights: Fostemsavir (Rukobia) for HIV
Fostemsavir (Rukobia) is indicated in combination with other antiretroviral medications in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.
Rukobia is a glycoprotein 120-directed attachment inhibitor. It is a prodrug that is hydrolyzed to its active moiety, temsavir. Temsavir binds directly to the glycoprotein 120 subunit of the HIV-1 envelope and selectively inhibits the interaction between the virus and cellular CD4 receptors. In addition, temsavir can inhibit glycoprotein 120-dependent post-attachment steps that are required for viral entry into host cells.
Temsavir reaches maximum plasma concentrations 2 hours after oral administration and displays an elimination half-life of 11 hours. Age, ethnicity, race, and sex do not affect its pharmacokinetics.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025